A double-blind, randomized controlled study of the effects of celecoxib on clinical symptoms and cognitive impairment in patients with drug-naïve first episode schizophrenia: pharmacogenetic impact of cyclooxygenase-2 functional polymorphisms
Wang D, Chen D, Xiu M, Wang L, Kosten T, Zhang X. A double-blind, randomized controlled study of the effects of celecoxib on clinical symptoms and cognitive impairment in patients with drug-naïve first episode schizophrenia: pharmacogenetic impact of cyclooxygenase-2 functional polymorphisms. Neuropsychopharmacology 2023, 49: 893-902. PMID: 37903861, PMCID: PMC10948781, DOI: 10.1038/s41386-023-01760-8.Peer-Reviewed Original ResearchFirst-episode SCZ patientsClinical symptomsSCZ patientsCOX2 inhibitorsCyclooxygenase-2Drug-naïve first-episode schizophreniaCognitive impairmentCentral nervous system inflammationNervous system inflammationPlacebo-controlled trialSubscale scoresPANSS total scoreFirst-episode schizophreniaEffect of celecoxibCase-control studyPathogenesis of schizophreniaNegative Syndrome ScaleArachidonic acid pathwayCOX-2 geneCelecoxib 400Pharmacogenetic impactRs5275 polymorphismPlacebo groupSystem inflammationPANSS total